Abstract
Mutations in the promoter region of the factor IX gene result in hemophilia B Leyden, which is characterized by considerable improvement in the disease after puberty. We have found that distinct nucleotide substitutions at the -6 position in the Leyden-specific (LS) region are associated with a different severity of hemophilia B. The proband (aged 2) from one family is a severe hemophiliac with factor IX activity (F.IXC) and antigen (F.IXAg) levels less than 1.0U/dl. F.IXC and F.IXAg levels in two affected uncles are approximately 30% of normal levels. The LS region was targeted for analysis because the phenotypes suggested the inheritance of a factor IX Leyden gene. An abnormal TaqI digestion pattern was found in amplified DNA from the proband, and sequencing showed a G (-6) to C transversion that was linked to the disease in the family. In another family, two brothers (aged 8 and 9) suffer from mild hemophilia with F.IXC ranging from 7 to 10 U/dl and F.IXAg from 3 to 4 U/dl. They are the only documented members of the family with a bleeding tendency. Denaturing gradient gel electrophoresis on amplified fragments from one of the patient's genomic DNA corresponding to the 8 exons and flanking sequences of the factor IX gene suggested a defect only in a segment from the 5′ region. This segment showed an altered TaqI digestion pattern, and sequencing demonstrated a G(-6) to A transition that was traced to the patients's mother and a grandmother. The different phenotypes associated with the G (-6) to A purine nucleotide transition compared with a G(-6) to C transversion provide evidence that this area is directly involved in the regulation of the human factor IX gene expression in vivo by binding of regulatory factors. The ability to predict that the conditions of a hemophilia B patient will improve with age has important implications for genetic counseling of the family. Therefore, the LS region should always be included when scanning the factor IX gene for mutations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Attree O, Vidaud D, Vidaud M, Amselem S, Lavergne JM, Goossens M (1989) Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior. Genomics 4:266–272
Bahnak BR, Lavergne JM, Verweij C, Rothschild C, Pannekoek H, Larrieu MJ, Meyer D (1988) Carrier detection in severe (type III) von Willebrand disease using two intragenic restriction fragment length polymorphisms. Thromb Haemost 60:178–181
Bottema CDK, Bottema MJ, Ketterling RP, Yoon H-S, Janco RL, Phillips III JA, Sommer SS (1991) Why does the human factor IX gene have a G+C content of 40%? Am J Hum Genet 49:839–850
Briet E, Bertina RM, Tilburg NH van, Veitkamp JJ (1982) A sexlinked hereditary disorder that improves after puberty. N Engl J Med 306:788–790
Crossley M, Brownlee GG (1990) Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 345:444–446
Crossley M, Winship PR, Austen DEG, Rizza CR, Brownlee GG (1990) A less severe form of haemophilia B Leyden. Nucleic Acids Res 18:4633
Giannelli F, Green PM, High KA, Sommer S, Lillicrap DP, Ludwig M, Olek K, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG (1991) Haemophilia B: database of point mutations and short additions and deletions — second edition. Nucleic Acids Res 19:2193–2219
Gyllensten UB, Erlich HA (1988) Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci USA 85:7652–7656
Hall A, Chuansumrit A, Peake IR, Winship PR (1992) A single base pair deletion in the promoter region of the factor IX gene is associated with haemophilia B (abstract). Br J Haematol 80 [Suppl 1]:3
Hirosawa S, Fahner JB, Salier JP, Wu C-T, Lovrien EW, Kurachi K (1990) Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden. Proc Natl Acad Sci USA 87:4421–4425
Ketterling RP, Bottema CDK, Phillips III JA, Sommers SS (1991) Evidence that descendents of three founders constitute about 25% of hemophilia B in the United States. Genomics 10:1093–1096
Langdell RD, Wagner RH, Brinkhous KM (1953) Effect of anti-hemophilic factor IX on one stage clotting test. J Lab Clin Med 41:637–641
Lerman LS, Silverstein K (1987) Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 155:482–501
Østerud B, Kasper CK, Lavine KK, Prodanos C, Rapaport SI (1981) Purification and properties of an abnormal blood coagulation factor IX (factor IXBm): kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Thromb Haemost 45:55–59
Pang CP, Crossley M, Kent G, Brownlee GG (1990) Comparative sequence analysis of mammalian factor IX promoters. Nucleic Acids Res 18:6731–6732
Pavlevtich NP, Pabo CO (1991) Zinc finger— DNA recognition: crystal structure of a Zif268-DNA complex at 2. 1 Å. Science 252:809–817
Picketts DJ, D'Souza C, Bridge PJ, Lillicrap D (1992) An A to T transversion at position -5 of the factor IX promoter results in hemophilia B. Genomics 12:161–163
Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briët E (1988) The putative factor IX gene promoter in hemophilia B Leyden. Blood 72:1074–1076
Saad S, Green PM, Murday V, Minford A, Giannelli F (1992) A novel promoter mutation in the factor IX gene (abstract). Br J Haematol 80 [Suppl 1]:16
Saiki RK, Gelfland DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Ehrlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487–491
Veitkamp JJ, Meilof J, Remmelts HG, Vlerk D van der, Loeliger EA (1970) Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol 7:82–90
Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K (1985) Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 24:3736–3750
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vidaud, D., Tartary, M., Costa, JM. et al. Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling. Hum Genet 91, 241–244 (1993). https://doi.org/10.1007/BF00218264
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00218264